## Zoe Moodie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1773481/publications.pdf Version: 2024-02-01



ZOF MOODIE

#	Article	IF	CITATIONS
1	Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. Journal of Infectious Diseases, 2022, 225, 332-340.	4.0	1
2	Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand. Human Immunology, 2022, 83, 53-60.	2.4	3
3	Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge. Cell Reports Medicine, 2022, 3, 100658.	6.5	12
4	Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. Journal of Infectious Diseases, 2022, 226, 246-257.	4.0	11
5	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021, 372, 1413-1418.	12.6	468
6	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults. New England Journal of Medicine, 2021, 384, 1089-1100.	27.0	144
7	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and TÂcells. Cell Reports Medicine, 2021, 2, 100354.	6.5	316
8	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. PLoS Pathogens, 2021, 17, e1010016.	4.7	1
9	Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults. Clinical Infectious Diseases, 2020, 71, 1481-1490.	5.8	9
10	Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial. Nature Communications, 2020, 11, 5578.	12.8	30
11	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. PLoS ONE, 2020, 15, e0234236.	2.5	9
12	Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus. Vaccine, 2020, 38, 3531-3536.	3.8	12
13	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: AÂrandomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Medicine, 2020, 17, e1003038.	8.4	27
14	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. Scientific Reports, 2020, 10, 2093.	3.3	17
15	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. MSphere, 2020, 5, .	2.9	3
16	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Medicine, 2020, 17, e1003117.	8.4	8
17	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS ONE, 2020, 15, e0226803.	2.5	16
18	Title is missing!. , 2020, 15, e0234236.		0

ZOE MOODIE

#	Article	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0234236.		Ο
20	Title is missing!. , 2020, 15, e0234236.		0
21	Title is missing!. , 2020, 15, e0234236.		0
22	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. Frontiers in Immunology, 2019, 10, 2741.	4.8	25
23	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. American Journal of Tropical Medicine and Hygiene, 2019, 101, 164-179.	1.4	9
24	Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. Journal of Infectious Diseases, 2018, 217, 742-753.	4.0	80
25	Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. PLoS ONE, 2018, 13, e0207878.	2.5	5
26	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV,the, 2018, 5, e366-e378.	4.7	86
27	Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. New England Journal of Medicine, 2018, 379, 327-340.	27.0	557
28	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. Journal of Infectious Diseases, 2016, 213, 541-550.	4.0	28
29	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. PLoS ONE, 2016, 11, e0147812.	2.5	42
30	Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS ONE, 2016, 11, e0152952.	2.5	4
31	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. PLoS ONE, 2015, 10, e0136626.	2.5	23
32	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS ONE, 2015, 10, e0137666.	2.5	30
33	Optimizing Viable Leukocyte Sampling from the Female Genital Tract for Clinical Trials: An International Multi-Site Study. PLoS ONE, 2014, 9, e85675.	2.5	73
34	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study. PLoS ONE, 2014, 9, e108631.	2.5	23
35	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infectious Diseases, The, 2014, 14, 388-396.	9.1	108
36	Vaccine Enhancement Confirmed among Men in HVTN 503-S, Final Results from a Recall Study of Phambili Participants. AIDS Research and Human Retroviruses, 2014, 30, A32-A33.	1.1	0

ZOE MOODIE

#	Article	IF	CITATIONS
37	Incident Herpes Simplex Virus Type 2 Associated with HIV Infection in Phambili. AIDS Research and Human Retroviruses, 2014, 30, A29-A30.	1.1	0
38	New clinical trial designs for HIV vaccine evaluation. Current Opinion in HIV and AIDS, 2013, 8, 437-442.	3.8	6
39	Quantitative and Qualitative Differences in the T Cell Response to HIV in Uninfected Ugandans Exposed or Unexposed to HIV-Infected Partners. Journal of Virology, 2013, 87, 9053-9063.	3.4	19
40	Comparison of Sexual Behavior and HIV Risk between Two HIV-1 Serodiscordant Couple Cohorts: The CHAVI 002 Study. PLoS ONE, 2012, 7, e37727.	2.5	5
41	Comparing and combining data across multiple sources via integration of pairedâ€sample data to correct for measurement error. Statistics in Medicine, 2012, 31, 3748-3759.	1.6	11
42	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infectious Diseases, The, 2011, 11, 507-515.	9.1	330
43	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS ONE, 2011, 6, e21225.	2.5	131
44	Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals. Journal of Virology, 2011, 85, 3507-3516.	3.4	38
45	Virus-Specific CD8 <sup>+</sup> T-Cell Responses Better Define HIV Disease Progression than HLA Genotype. Journal of Virology, 2010, 84, 4461-4468.	3.4	50
46	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). PLoS ONE, 2010, 5, e13579.	2.5	47
47	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis. Lancet, The, 2008, 372, 1894-1905.	13.7	670
48	Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. Journal of Immunological Methods, 2007, 323, 39-54.	1.4	223
49	A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial. Vaccine Journal, 2006, 13, 1267-1277.	3.1	221
50	Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. Journal of Immunological Methods, 2006, 315, 121-132.	1.4	63
51	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIVâ€1 Candidate Vaccine Delivered by a Replicationâ€Defective Recombinant Adenovirus Vector. Journal of Infectious Diseases, 2006, 194, 1638-1649.	4.0	283
52	Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIVâ€I DNA Candidate Vaccine. Journal of Infectious Diseases, 2006, 194, 1650-1660.	4.0	200
53	Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines. Journal of Virology, 2003, 77, 12764-12772.	3.4	90
54	Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting. Journal of Virology, 2003, 77, 799-803.	3.4	197